Ignite Creation Date:
2024-05-06 @ 4:58 PM
Last Modification Date:
2024-10-26 @ 2:19 PM
Study NCT ID:
NCT05152212
Status:
COMPLETED
Last Update Posted:
2024-04-22
First Post:
2021-11-09
Brief Title:
Study of LVGN7409 CD40 Agonist Antibody in Locally Advanced Metastatic or RecurrentRefractory Malignancy
Sponsor:
Lyvgen Biopharma Holdings Limited
Organization:
Lyvgen Biopharma Holdings Limited
Study Overview
Official Title:
An Open Label Phase I Trial of LVGN7409 as Single Agent in Locally Advanced Metastatic or RecurrentRefractory Malignancy
Status:
COMPLETED
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study of LVGN7409-201 is designed to use a bridging dose escalation to quickly establish the maximum tolerated dose MTD andor the recommended dose for expansion RDE as well as the recommended Phase 2 doses RP2D of LVGN7409 as a single agent monotherapy in the treatment of locally advanced metastatic or recurrentrefractory malignancy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None